Table 3 Proportion of patients with incomplete follow-up.
From: The effect of varying analytical methods on estimates of anti-malarial clinical efficacy
| Â | Africa | Thailand | Overall |
|---|---|---|---|
Unadjusted Analysis | 7619 | 7790 | 15,409 |
Interrupted follow-up a | 360 (4.7%) | 1117 (14.3%) | 1477 (9.6%) |
Non-falciparum new infections | 40 (0.5%) | 1120 (14.4%) | 1160 (7.5%) |
Overall | 400 (5.3%) | 2237 (28.7%) | 2637 (17.1%) |
Adjusted Analysis b | 7619 | 5813 | 13,432 |
Interrupted follow-up a | 360 (4.7%) | 673 (11.6%) | 1033 (7.7%) |
Non-falciparum new infections | 40 (0.5%) | 1023 (17.6%) | 1063 (7.9%) |
P. falciparum new infections | 1864 (24.5%) | 323 (5.6%) | 2187 (16.3%) |
Unsuccessful genotyping | 107 (1.4%) | 99 (1.7%) | 206 (1.5%) |
Overall | 2371 (31.1%) | 2118 (36.4%) | 4489 (33.4%) |